Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies

DSpace Repository

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies

Author: Kauer, Joseph; Hoerner, Sebastian; Osburg, Lukas; Mueller, Stefanie; Maerklin, Melanie; Heitmann, Jonas S.; Zekri, Latifa; Rammensee, Hans-Georg; Salih, Helmut R.; Jung, Gundram
Tübinger Autor(en):
Kauer, Joseph
Hörner, Sebastian
Osburg, Lukas
Müller, Stefanie
Märklin, Melanie
Heitmann, Jonas S.
Zekri, Latifa
Rammensee, Hans-Georg
Salih, Helmut Rainer
Jung, Gundram
Published in: Journal For Immunotherapy of Cancer (2020), Bd. 8, Article e000621
Verlagsangabe: Bmj Publishing Group
Language: English
Full text: http://dx.doi.org/10.1136/jitc-2020-000621
ISSN: 2051-1426
DDC Classifikation: 570 - Life sciences; biology
610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)